Concomitant cisplatin and radiotherapy in a conventional and modified fractionation schedule in locally advanced head and neck cancer: a randomised phase II EORTC trial

European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)
H BartelinkMartine van Glabbeke

Abstract

A randomised phase II trial was initiated to explore the feasibility of concomitant cisplatin and radiotherapy with conventional fractionation (CF) or multiple fractions per day (MFD) for patients with locally advanced head and neck malignancies. The MFD schedule was designed to achieve higher tumour concentrations of cisplatin at the time of irradiation by reducing the number of radiation treatment weeks from 7 to 3, allowing recovery from side-effects of both irradiation and cystostatic drugs during the rest periods, while keeping the same total dose and overall treatment time. Patients were randomised between a conventional fractionation scheme (CF) of 70 Gy in 7 weeks with 2 Gy per fraction with a daily dose of 6 mg/m(2) cisplatin and a modified fractionation scheme (MFD) delivering three fractions of 1.6 Gy per day, in weeks 1, 4 and 7, keeping the same overall treatment time and total dose. In the modified treatment regime, a daily dose of 10 mg/m(2) cisplatin was administered. 53 patients were entered in this trial and radiotherapy was given according to the schedule to all patients in both treatment arms. Cisplatin was given during the whole course of radiotherapy to only one quarter of the patients in the CF arm, stopp...Continue Reading

References

Dec 1, 1992·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·J C HoriotM Bolla
Jan 1, 1991·Cancer Chemotherapy and Pharmacology·P M TerheggenL den Engelse
Nov 1, 1990·International Journal of Radiation Oncology, Biology, Physics·A C Begg
Aug 1, 1990·International Journal of Radiation Oncology, Biology, Physics·E Van der SchuerenE Van Limbergen
Mar 1, 1987·International Journal of Radiation Oncology, Biology, Physics·L Dewit
May 1, 1986·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·H BartelinkG A Hart
Jan 1, 1996·Clinical Oncology : a Journal of the Royal College of Radiologists·D M BottomleyR H Phillips

❮ Previous
Next ❯

Citations

Jun 7, 2012·Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology·Syed Nabil, Nabil Samman
Aug 19, 2008·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·Charlotte L ZuurCoen R N Rasch
Oct 24, 2006·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·Guido B van den BroekCoen R N Rasch
Mar 22, 2015·Journal of Oral and Maxillofacial Surgery : Official Journal of the American Association of Oral and Maxillofacial Surgeons·Wataru KobayashiYoshihiro Takai
Aug 16, 2014·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Stephen SonisUNKNOWN TRIAD Burden of Illness Investigators
Feb 28, 2018·Expert Review of Anticancer Therapy·Rosario MazzolaFilippo Alongi
Dec 15, 2010·The Cochrane Database of Systematic Reviews·Anne-Marie GlennyUNKNOWN CSROC Expert Panel
Dec 21, 2007·Journal of Radiation Research·Junichi KitagawaShigeji Matsumoto
Mar 9, 2019·JACC. Basic to Translational Science·Suzanne M EkenLars Maegdefessel
Apr 17, 2021·The Lancet Oncology·Claire PetitUNKNOWN MACH-NC and MARCH Collaborative Groups

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.